|Day Low/High||156.25 / 160.08|
|52 Wk Low/High||145.86 / 179.92|
I wouldn't expect a lot in the way of economic shutdowns, at least not unless clear evidence presents that people are getting sicker from Omicron.
The lingering effects of the pandemic have been hard on smaller biotech and healthcare stocks, but the worm could turn next year.
They say that breaking up is hard to do Now I know I know that it's true Don't say that this is the end Instead of breaking up I wish that we were making up again - Neil Sedaka, Breaking Up Is Hard To Do While many embrace the speculative orgy of...
* My revised levels I don't want there to be any ambiguity about the size of my positions, or about my buy and short levels, as I strive for as much transparency as possible. This column is a continued commitment towards that sort of disclosure. "Wh...
These moves could serve as a benchmark for other bigger, older, and perhaps bloated companies. Here are some candidates.
J&J will be separating into two distinct firms, but not right away.
This morning Johnson & Johnson joined a long and growing list, including a recently announced disaggregation, of companies that are breaking into parts. AT&T is already disaggregating - with the Warner/Discovery deal - and perhaps should go even fu...
There is a lingering apprehension that the moment has passed for many of these names.
While cryptocurrencies are indeed an asset class, and they are divisible, they do not serve as a medium of exchange, and remain unproven as a store of value.
All eyes will be on JNJ as it releases its numbers Tuesday.
Plus, an FDA advisory panel gives a unanimous boost to a Moderna booster shot and Boeing slumps on a negative news report.
As you mark your October calendar for what I shared earlier, also keep your eyes on Oct. 14-15. Those are the days a panel of FDA advisors will meet to discuss whether to recommend booster shots of Covid-19 vaccines from Moderna and Johnson & Johnso...
Let's look at that recent downgrade of 'dull' Morgan Stanley and see why exciting is best left for the stadiums and amusement parks -- and not stocks.
Investors are increasingly looking to the companies involved in clinical trials. Here are six favorite names in this space.
It was as if markets heard what they wanted to hear, when it was actually much more simple: markets heard exactly what they had anticipated.
How come this decision was so opaque to so many?
It's time to turn to the chart to determine whether the pullback is an opportunity to buy or if it is something more.
I could be wrong, but as far as I can tell, nobody else is telling the story about the sudden movement in these yields.
The fiscal football remains a greater threat this week than anything Fed Chair Jerome Powell says on Zoom this Friday.
Investors come into this week with 'all eyes' on the Kansas City Fed's economic symposium come week's end.
AbbVie has been a Sarge fave for a long time. Sarge has been rewarded for trusting this firm's management when they acquired Allergan as a means toward replacing expected reductions in cash flows moving forward as the firm's patents for winder dru...
We're seeing a group move in pharma right now, so let's sort it out, pill by pill.
A wall of liquidity seems to absorb every dip. But there are also enough reasons to be ever vigilant.
To the melody of the Byrds' famed song, I want you to know: There's a time to buy the industrials, a time to sell the banks; a time to bid for health cares, a time to dump the techs. ...